Incidence, Risk Factors, and Timing of Elevated Intraocular Pressure After Intravitreal Triamcinolone Acetonide Injection for Macular Edema Secondary to Retinal Vein Occlusion: SCORE Study Report 15
06/2015
Journal Article
Authors:
Aref, A.;
Scott, I.;
Oden, N.;
Ip, M.;
Blodi, B.;
VanVeldhuisen, P.;
Group, T.S.C.O.R.E.Stud
Secondary:
JAMA Ophthalmol
URL:
http://www.ncbi.nlm.nih.gov/pubmed/26086920
Keywords:
intraocular pressure elevation; intravitreal triamcinolone acetonide; macular edema; retinal vein occlusion; SCORE Study; visual acuity
Abstract:
Importance: The Standard of Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study showed that intravitreal triamcinolone acetonide (IVTA) is effective at reducing macular edema and improving visual acuity in participants with retinal vein occlusion. Secondary analysis of the incidence, risk factors, and timing of intraocular pressure (IOP) elevation occurring after IVTA provides guidance for clinical decision making and management of patients treated with IVTA. Objective: To investigate the incidence, risk factors, and time course of IOP elevation in participants in the SCORE Study. Design, Setting, and Participants: Secondary analysis conducted from August through December 2014 of a prospective, randomized clinical trial featuring an evaluable population conducted at 75 clinical sites. Six hundred eighty-two patients with macular edema secondary to retinal vein occlusion were enrolled in the study. The SCORE Study enrollment period ran from November 4, 2004, to February 29, 2008, with participant follow-up ending February 28, 2009. Interventions: Study participants were randomized to standard of care, 1 mg of IVTA, or 4 mg of IVTA therapy and followed up for a mean (SD) of 24.7 (10.3) months. Main Outcomes and Measures: Intraocular pressure elevation greater than 10 mm Hg from baseline. Results: Kaplan-Meier incidences of IOP elevation greater than 10 mm Hg from baseline at 36 months were 0.02 (95% CI, 0.01-0.06), 0.09 (95% CI, 0.05-0.14), and 0.45 (95% CI, 0.38-0.53) in the standard of care, 1-mg IVTA, and 4-mg IVTA groups, respectively. The rates of IOP-related events were higher for the 4-mg IVTA group compared with the other groups (P
